Critical Contrast: PetVivo (NASDAQ:PETV) and Nyxoah (NASDAQ:NYXH)

PetVivo (NASDAQ:PETV) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Profitability

This table compares PetVivo and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PetVivo	-1,036.82%	-1,038.50%	-266.37%
Nyxoah	-908.32%	-42.00%	-33.43%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for PetVivo and Nyxoah, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0	0	0	0	N/A
Nyxoah	0	0	5	0	3.00

Nyxoah has a consensus price target of $17.20, suggesting a potential upside of 79.92%. Given Nyxoah’s higher possible upside, analysts plainly believe Nyxoah is more favorable than PetVivo.

Institutional and Insider Ownership

24.6% of PetVivo shares are owned by institutional investors. 20.1% of PetVivo shares are owned by insiders. Comparatively, 17.1% of Nyxoah shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares PetVivo and Nyxoah”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$970,000.00	12.39	-$10.95 million	($0.79)	-0.76
Nyxoah	$4.79 million	49.76	-$46.77 million	($1.64)	-5.83

PetVivo has higher earnings, but lower revenue than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than PetVivo, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

PetVivo has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500.

Summary

Nyxoah beats PetVivo on 7 of the 13 factors compared between the two stocks.

About PetVivo

PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.